| |
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.. 
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now. 
|
|
| By Nick Paul Taylor Vaxess Technologies has generated early clinical evidence in support of its delivery patch, linking the device to seroprotection rates of over 90% when used to administer an influenza vaccine in a phase 1 trial. |
|
|
|
By Nick Paul Taylor Xeris Biopharma has the green light to take its subcutaneous levothyroxine into phase 2. After talking to the FDA, the company outlined plans to start a midphase trial of the investigational alternative to oral hypothyroidism therapy in the second half of next year. |
By Nick Paul Taylor Midatech Pharma has identified a path past its cash crunch. With its runway set to end in March, the drug delivery specialist has secured financing and struck a deal to buy Bioasis Technologies to transition into a rare disease biotech. |
By Nick Paul Taylor Thea Pharma’s work to eliminate preservatives from latanoprost formulations has landed it a FDA nod in open-angle glaucoma and ocular hypertension, clearing the company to launch a differentiated rival to the incumbent eye drops. |
|
Discovering and developing a new drug is a complex and time-consuming endeavor. A carefully devised hit finding strategy is, therefore, essential when looking for validated hit series with a good chance of being developed into drug-like compounds. This ebook considers witch method to use, hit finding trends, and new technologies. Download now. 
|
|
By Sharon Klahr Coey When it comes to pharma’s reputation at the end of 2022, there’s some good news and some bad news. The bad news is that according to the Harris Poll, pharma’s rep in the U.S. is continuing to drop from its peak in of 62% positive in December 2020 when the first COVID mRNA shots were authorized by the FDA. But it’s not all doom and gloom for the industry, at a 45% positive rating it’s still up from a pre-pandemic 32%, so that’s good. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the medtech industry’s highest paid CEOs. Plus, we cover Theranos' COO's prison sentence, highlights from the American Society of Hematology annual meeting and other top headlines from this week. |
|
|---|
|
|
|
Want to boost sales with HCP specific market access pull-through messaging tailored to your patient population? Discover how Access Genius can drive radical brand prescription growth and amplify sales with a 4:1 proven ROI. Download the Infographic to learn more. 
|
|
Multimedia Plan Your ASH’22 Attendance In No Time | Interactive Planner Sponsored by: Ferma.AI, a product of ZoomRx |
Podcast How can Medical Affairs divisions bring greater value to their organizations and practitioners every day? Sponsored by: Medscape Medical Affairs |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
| |
|
